News

• 5 Oct, 2023
  Kallelse till extra bolagsstämma i Spago Nanomedical AB (publ)
• 5 Oct, 2023
  Notice to the Extraordinary General Meeting of Spago Nanomedical AB (publ)
• 5 Oct, 2023
  Spago Nanomedical föreslår en fullt garanterad företrädesemission av units om cirka 30,6 MSEK för att avancera Tumorad
• 5 Oct, 2023
  Spago Nanomedical proposes a fully guaranteed rights issue of units of approximately SEK 30.6 million to advance Tumorad
• 31 Jul, 2023
  Spago Nanomedical interim report January-June 2023
• 31 Jul, 2023
  Spago Nanomedical delårsrapport januari-juni 2023
• 28 Jun, 2023
  Spago Nanomedical uppdaterar om den kliniska fas IIa-studien SPAGOPIX-02
• 28 Jun, 2023
  Spago Nanomedical updates on the clinical phase IIa study SPAGOPIX-02
• 13 Jun, 2023
  Spago Nanomedical stärker Tumorad® genom nytt vetenskapligt råd
• 13 Jun, 2023
  Spago Nanomedical strengthens Tumorad® by establishment of Scientific Advisory Board